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Abstract 
Background: Malaria is a public health burden and a major cause for morbidity and mortality in Ethiopia. Malaria 
also places a substantial financial burden on families and Ethiopia’s national economy. Economic evaluations, with 
evidence on equity and financial risk protection (FRP), are therefore essential to support decision-making for policy-
makers to identify best buys amongst possible malaria interventions. The aim of this study is to estimate the expected 
health and FRP benefits of universal public financing of key malaria interventions in Ethiopia.
Methods: Using extended cost-effectiveness analysis (ECEA), the potential health and FRP benefits were estimated, 
and their distributions across socio-economic groups, of publicly financing a 10% coverage increase in artemisinin-
based combination therapy (ACT), long-lasting insecticide-treated bed nets (LLIN), indoor residual spraying (IRS), and 
malaria vaccine (hypothetical).
Results: ACT, LLIN, IRS, and vaccine would avert 358, 188, 107 and 38 deaths, respectively, each year at a net govern-
ment cost of $5.7, 16.5, 32.6, and 5.1 million, respectively. The annual cost of implementing IRS would be two times 
higher than that of the LLIN interventions, and would be the main driver of the total costs. The averted deaths would 
be mainly concentrated in the poorest two income quintiles. The four interventions would eliminate about $4,627,800 
of private health expenditures, and the poorest income quintiles would see the greatest FRP benefits. ACT and LLINs 
would have the largest impact on malaria-related deaths averted and FRP benefits.
Conclusions: ACT, LLIN, IRS, and vaccine interventions would bring large health and financial benefits to the poorest 
households in Ethiopia.
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Background
Malaria prevention and control has been prioritized over 
the past decade in many national health sector plans. 
As a result, remarkable progress was made worldwide 
in reducing incidence and mortality from malaria [1, 
2]. Due to the expansion of effective strategies, between 
2001 and 2013, malaria incidence has dropped by 30% [1, 
2]. Despite such progress, malaria remains a major public 
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development of many countries [1, 2]. Nearly one-half of 
the world population lives in malaria-endemic countries 
[3]. In 2016 alone, there were an estimated 216 million 
cases and 445,000 deaths attributable to malaria world-
wide [4]. Sub-Saharan Africa accounts for 90% of both 
cases and deaths due to malaria [4]. Malaria control is 
unequally distributed across socioeconomic groups and 
the rates of insecticide- and drug-resistance are increas-
ing. Further scale-up of cost-effective malaria interven-
tions with sustainable financing mechanisms is therefore 
urgently needed [5].
Ethiopia has made notable progress towards malaria 
control [6, 7]. Nationally, the prevalence of malaria has 
declined from 5 to 3% over 2010–2015 [5, 8, 9]. During 
the same period, malaria-related deaths were reduced 
by 40% [5]. Scale-up of effective anti-malaria interven-
tions at the primary health care level and improved com-
munity engagement were major contributing factors to 
this progress [10]. There is little evidence from Ethio-
pia about other factors that might have contributed to 
malaria decline (e.g. climate change, housing structures 
and urbanization). However, despite significant progress, 
much remains to be done in the fight against malaria in 
Ethiopia, where about 2.6 million cases and 5000 deaths 
were estimated for the year 2016 [4]. Additionally, the 
2015 malaria indicator survey shows that only 40% of the 
population at risk correctly use insecticide-treated bed 
nets [9].
Malaria prevention and control are major priorities for 
Ethiopia’s health sector transformation plan (HSTP) [11]. 
The primary strategies include rolling out long-lasting 
insecticide-treated bed nets (LLIN) and insecticide resid-
ual spray (IRS) for at-risk population [10, 12]. Similarly, 
artemisinin-based combination therapy (ACT) is recom-
mended as first-line treatment of uncomplicated malaria 
[10, 12]. Ethiopia has committed to end malaria by 2030 
and adopted global malaria control and elimination strat-
egies [12]. As the country moves towards elimination 
by 2030, tests that are more sensitive will be required to 
detect subclinical malaria infection to prevent disease 
transmission [13]. A malaria vaccine (i.e. RTS,S/AS01) 
could help curb the malaria burden. However, the effi-
cacy of the vaccine is partial and presents rapid waning 
immunity [14, 15].
Malaria is endemic in many regions of Ethiopia with 
marked seasonal and geographic variation. Nearly 60% 
of the total population reside in high-risk areas [10, 12]. 
In addition to its public health impact, malaria imposes 
a large financial burden on households, consuming on 
average 7% of household income [16, 17]. Marginalized 
and economically vulnerable populations are also at a 
higher risk of acquiring malaria and of experiencing fatal 
consequences because of limited health care access and 
the inability to pay for it [1, 18, 19]. Malaria spending is 
estimated to cost Ethiopia about $200 million annually 
or 10% of its total health expenditure [20]. Hence, reduc-
ing malaria disease burden has the potential to improve 
socioeconomic development [21].
The recent attention to universal health coverage 
(UHC) has provided context to explore mechanisms that 
would expand access to malaria prevention and treat-
ment services in Ethiopia [22]. This would also help 
address the high rate (33%) of out-of-pocket (OOP) pay-
ments [20]. Given that a quarter of the Ethiopian popu-
lation lives below the national poverty line [23], OOP 
malaria treatment costs can be an important barrier to 
access effective treatment and in pushing households into 
impoverishment in Ethiopia. Accounting for non-health 
benefits is essential to reduce health inequalities and 
contribute to the objectives of UHC [22]. Financial risk 
protection (FRP) is an important policy objective and can 
improve access to all needed quality health services with-
out financial hardship [24, 25].
In this paper, the aim is to estimate the potential health, 
FRP, and equity benefits of universal public finance of 
scaling up selected malaria prevention and treatment 
interventions in Ethiopia [26]. This will support poli-
cymakers in jointly considering health gains, FRP and 
equity benefits in resource allocation related decisions.
Methods
Using extended cost-effectiveness analysis (ECEA), we 
consider the costs and health impact of malaria inter-
ventions across population subgroups and estimate the 
FRP impact on households in Ethiopia [26]. Building on 
a recent ECEA of malaria vaccine [28], and using a static 
disease model, are quantified, across socioeconomic 
groups (i.e. income quintiles), for each of four malaria 
interventions (ACT, LLIN, IRS, and malaria vaccine): the 
number of malaria-related deaths and OOP expenditures 
averted; the corresponding household FRP provided; and 
the implementation costs. Furthermore, ECEA is also 
applied across malaria transmission intensities to account 
for geographic variation of malaria (see Additional file 1: 
Appendix Table S2).
Malaria interventions
Large scale use of LLINs is a key strategy to reduce 
malaria burden [29]. A meta-analysis showed that LLIN 
was effective in both reducing malaria cases (by 50%) and 
malaria deaths (by 18%) [27]. IRS can eliminate malaria 
vectors by applying a residual insecticide to the internal 
walls and ceilings of homes [2, 30], and its use has been 
shown to decrease plasmodium falciparum malaria by 
29% [31]. A complete cure can be expected in 95% of 
falciparum malaria cases treated with ACT [32]. The 
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proportion of Plasmodium falciparum malaria in Ethio-
pia totals about 80–90% of all malaria cases [9]. Lastly, a 
recent clinical trial showed a 26% reduction in the num-
ber of episodes and hospital admissions, in children 
under 2  years of age, following three doses of malaria 
vaccine (currently under development) [14].
Health benefits
Population at risk of malaria (accounting for 60% of total 
population—defined as areas with annual incidence > 0 
per 1000 population) is the target population for LLIN 
and IRS (Table  1) [12]. Similarly, the estimated number 
of annual malaria cases and birth cohorts born in at-risk 
areas were the target populations for ACT and vaccine, 
respectively [12, 14]. Target populations were split into 
income quintiles for LLIN, IRS, and ACT interventions. 
As for the vaccine, quintile-specific total fertility rates 
were applied in order to differentiate between the num-
ber of susceptible individuals per income quintile (see 
Additional file  1: Appendix). For each intervention, in 
order to calculate malaria prevalence by at-risk popula-
tion per income quintile, first the relative risk of malaria 
prevalence by income quintile is estimated for the gen-
eral population [9, 10]. These stratified relative risks were 
multiplied by average malaria prevalence, in order to split 
prevalence rates across income quintiles for populations 
at risk (see Additional file 1: Appendix) [9, 10].
The baseline coverage (before introduction of universal 
public financing) was 40% for LLIN and 29% for IRS and 
their respective coverage by income quintile was sourced 
from the 2016 malaria indicator survey (MIS) (Table  1) 
[9]. LLIN use, rather than its possession, was selected as 
a proxy parameter because the actual use of LLIN reflects 
behavioural change [33]. The percentage for whom care 
was sought among children who had fever in the past 
2  weeks was used as a proxy for probability of seeking 
malaria care and baseline ACT coverage (35%) [34, 35]. A 
10% incremental coverage across quintiles was assumed 
for each intervention. For the vaccine, in addition to the 
10% incremental increase in coverage, a scenario with 
coverage scale-up from 0 to 33% was also considered 
(since this is the national coverage level of the basic child 
immunization programme) [34].
Before intervention, 2.6 million cases and 5000 deaths 
attributed to malaria were assumed to occur annually in 
Ethiopia [4]. On average, 1% of all malaria cases would 
be hospitalized, according to the integrated disease sur-
veillance database [36, 37]. Severe and mild cases were 
treated as inpatient and outpatient cases, respectively. 
Deaths averted by each intervention were calculated 
as a product of disease incidence, case fatality ratio, 
intervention efficacy and incremental coverage (see 
Additional file 1: Appendix). 
Financial consequences for households
Both inpatient and outpatient care of malaria can impose 
an economic burden to individual households. Direct 
medical, non-medical, and indirect costs were extracted 
from two previously published studies [18, 42]. Before 
universal public finance (UPF) of each intervention, indi-
viduals seeking malaria care would pay about $6 and $66 
out-of-pocket (OOP) costs for outpatient and inpatient 
treatment, respectively [18, 42]. Even if there were no 
OOP payments for preventive interventions, the three 
malaria preventive interventions (i.e. LLIN, IRS, vaccine) 
would lower the risk of malaria and thus household OOP 
expenditures related to malaria treatment. The amount of 
OOP expenditures averted per income quintile was quan-
tified, before and after UPF. OOP expenditures averted 
depended on: target population, incremental coverage, 
health care use, OOP payments, and preventive interven-
tion effectiveness (see Additional file 1: Appendix).
Financial risk protection benefits
The financial risk faced by households depends on the 
malaria burden, intervention coverage, and probability 
of seeking treatment. Annual consumption expenditures 
were extracted from the Ethiopian Household Income 
Consumption and Expenditure and Welfare Monitor-
ing Survey as a proxy for income [48]. In this study, a 
case of catastrophic health expenditures (CHE) was 
counted when total OOP spending for malaria treatment 
exceeded 10% of total household consumption expendi-
tures or 40% of capacity to pay (i.e. non-food total house-
hold consumption) [49, 50]. UPF introduction would 
avert a number of CHE cases following the reduction in 
incidence of OOP expenditures.
Intervention costs
The cost of each intervention was estimated from the 
health system perspective. Average unit cost estimates 
for preventive (LLIN, IRS, and vaccine) and curative 
(ACT) interventions were obtained from published stud-
ies (Table  1) [44–47]. The unit cost for LLIN included 
net price and delivery cost. Similarly, for IRS, insecticide 
cost accounted for 50%, spray campaign operations and 
labour for 26%, capital cost for 23% and other commodi-
ties accounted for 1% [44, 46, 47]. The average unit cost 
per fully vaccinated child included vaccine price, and sup-
plies accounted for 84%, and the remaining costs (16%) 
included training, transportation, waste management 
[45]. Unit cost of ACT comprised of human resources at 
58%, drug and pharmaceutical supplies at 25% and rest 
was indirect costs [43]. Patient and health system costs 
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Table 1 Extended cost-effectiveness analysis input parameters for  public financing of  selected malaria prevention 
and treatment interventions in Ethiopia
a Q1 stands for poorest income quintile,  Q5 for richest income quintile, and A for average
b Average unit cost estimate for inpatient visit
Parameter Value References
Epidemiology
 Population at risk of malaria (2016) 61,504,000 [12, 38]
 Population for malaria vaccine (2016 birth cohort) 1,984,000 Authors’ calculation [34, 38]
 Crude birth and child mortality rate, per 1000 population 32, 20 [34]
 Total fertility rate,  Q1–Q5;  A
a 6.4, 5.6, 4.9, 4.3, 2.6; 4.6 [34]
 Average household size 4.2 [38]
 Number of malaria deaths in the general population, population at risk, 
and children
5000; 3767; 1790 [4, 39]
 Prevalence of malaria in population at risk,  Q1–Q5; A 4.6; 3.1; 3.6; 2.2; 2.1; 3.1% [9, 10]
 Prevalence of malaria in children,  Q1–Q5; A 5, 3.3, 2.9, 2, 1.7, 3.1% [9]
 Probability of seeking malaria care,  Q1–Q5; A 23.8, 30.4, 33.0, 42.3, 50.5; 35.3% [34]
 Case fatality ratio for malaria outpatient and inpatient cases 0.19; 0.65% [3, 4]
 Proportion of malaria-related hospital admissions, Q1–Q5 1.00, 0.90, 0.96, 0.87, 0.83; 0.91% [36, 37]
 Effectiveness of LLIN 50% [27, 40]
 Effectiveness of indoor residual spraying (IRS) 29% [31]









 LLIN coverage before intervention,  Q1–Q5, A 26, 36, 42, 47, 44; 40% [9]
 LLIN coverage after intervention,  Q1–Q5, A 36, 46, 52, 57, 54; 50% [12] Authors’ assumption
 IRS coverage before intervention,  Q1–Q5, A 35, 35, 36, 28, 11; 29% [9]
 IRS coverage after intervention,  Q1–Q5, A 45, 45, 46, 38, 21; 39% [12] Authors’ assumption
 Malaria vaccine coverage before intervention,  Q1–Q5, A 0 [15]
 Malaria vaccine coverage after intervention,  Q1–Q5, A 10, 10, 10, 10, 10; 10% Authors’ assumption
 Malaria vaccine coverage after intervention,  Q1–Q5, A (fully immunized 
coverage)
19, 31, 30, 40, 58; 33% [34]
 ACT coverage before intervention,  Q1–Q5, A 24, 30, 33, 42, 51; 35% [34]
 ACT coverage after intervention,  Q1–Q5, A 34, 40, 43, 52, 61; 45% Authors’ assumption
Costs (2016 $)
 Out-of-pocket outpatient costs,  Q1–Q5, A $6.4, 6.8, 5.5, 6.6, 5.7; 6.2 [42]
 Out-of-pocket inpatient costs $65.9 [18]
 Unit cost of malaria treatment outpatient visit $7.3 [43]
 Unit cost of malaria treatment inpatient  visitb $31.6 [43]
 Unit cost of LLIN $5.4 [44]
 Unit cost per vaccinated child (3 doses) $26.0 [45]
 IRS unit cost per person protected $5.3 [46, 47]
 Household consumption expenditure  Q1–Q5, A $227, 369, 499, 671, 1422; 638 [48]
 Share of food in total consumption expenditure  Q1–Q5, A 48, 54, 51, 51, 58, 54% [23]
 GDP per capita 2016 $713 [38]
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were extracted from the literature and converted for the 
year 2016 using Ethiopia’s gross domestic product (GDP) 
deflator [38]. The total costs considered: target popula-
tion, intervention coverage and intervention unit cost.
Sensitivity analyses
The robustness of the findings were tested by using one-
way sensitivity analyses. Specifically, the value of malaria 
prevalence, case fatality ratio, intervention effectiveness, 
health services utilization, and intervention unit cost 
were varied by ± 20%, one at a time, to evaluate the inter-
ventions impact on the deaths and CHE averted, across 
income quintiles.
Results
Deaths and cases of CHE averted by malaria interventions
Increasing coverage (by 10%) of ACT, LLIN, IRS and 
vaccine among the population at risk would avert 358, 
188, 107 and 38 deaths per year in Ethiopia, respectively. 
The four interventions would also avert 440 (i.e. 10% of 
the baseline CHE), 220 (5%), 125 (3%) and 18 (2%) CHE 
cases annually, respectively. Among the interventions, 
LLIN and ACT would have the largest number of deaths 
averted and CHE cases averted. In addition, ACT and 
LLIN would avert $4,277,000 and $214,000 of OOP 
expenditure, respectively (Table 2).
Distribution of deaths and CHE cases averted by malaria 
intervention
All four interventions would save larger numbers of lives 
among the poor, due to the fact that the poor would face 
a higher malaria prevalence and associated risk factors. 
For example, ACT would avert twice as many deaths in 
the poorest income quintile as compared to the richest 
quintile (Fig. 1). 50% of the deaths averted would be con-
centrated in the poorest two quintiles. The distribution of 
deaths averted (by LLIN, IRS and ACT), from poorest to 
richest quintiles, would be 30, 20, 23, 14 and 13%, respec-
tively. Similarly, the distribution of deaths averted by the 
malaria vaccine would be 30, 22, 21, 16, and 11%, respec-
tively (Fig. 1).
For each intervention, the gradient in private OOP 
expenditures averted would be flat across quintiles 
Table 2 Total government costs, household out-of-pocket (OOP) expenditures averted, deaths averted, and catastrophic 
health expenditure (CHE) cases averted from  universal public finance of  selected malaria interventions at  10% 
incremental coverage, in Ethiopia




Deaths averted Cases 
of CHE 
averted
Artemisinin-based combination 5,721,000 4,277,000 358 440
Long-lasting insecticide-treated bed nets 16,489,000 214,000 188 220
Indoor residual spray 32,644,600 122,000 107 125








Q1 Q2 Q3 Q4 Q5
Income Quintile
Deaths Averted
Artemisinin-based combination treatment (ACT) Long-lasting Insecticidal bed nets












Fig. 1 Distribution of deaths averted by each malaria intervention per income quintile in Ethiopia
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as malaria prevalence would decrease with increas-
ing income, but the probability of seeking malaria care 
would increase as income goes up (Table  3). Therefore, 
the gains in private expenditures would be evenly dis-
tributed across income quintiles. Across the first three 
income quintiles, a greater number of CHE cases would 
be averted and the largest benefits would be among the 
poorest income quintile (Fig. 2).
The annual policy costs of UPF for 10% incremental 
coverage of ACT, LLIN, IRS and vaccine would be $5.7, 
16.5, 32.6, and 5.1 million, respectively. Similarly, due to 
declines in malaria cases through preventive interven-
tions, $241,000, $137,000 and $16,000 of government 
expenditures on malaria treatment would be averted 
annually by LLIN, IRS and malaria vaccine, respectively.
Most of these government savings would be observed 
within quintile one to three and LLINs would contribute 
to more than half of these savings. The rollout of malaria 
vaccines at 10% incremental coverage, under the rou-
tine immunization program in the country, would cost 
around $5 million and avert 38 deaths and reach $17 mil-
lion and avert about 120 deaths with 33% coverage.
Deaths and cases of CHE averted per million spent
The health benefits per $1 million invested on ACT, 
LLIN, IRS, and vaccine interventions would be 63, 11, 
3, and 7 lives, respectively. Similarly, they would reduce 
OOP expenditures by $1,560,000, 13,000, 3700 and 2800, 
respectively; with varying numbers of CHE cases averted 
by income quintile (see Additional file 1: Appendix, Figs. 
S1–S3).
Sensitivity analyses
The results of our univariate sensitivity analyses are 
described in Table 4 (and Additional file 1: Tables S3–S6). 
Generally, the distribution of health gains is highly prone 
to variations in malaria prevalence, case fatality ratio and 
intervention efficacy. The distributions in OOP expen-
ditures averted and CHE cases averted would be more 
sensitive to malaria prevalence, health care utilization, 
Table 3 Out-of-pocket private expenditures averted (in 2016 USD) per  income quintile for  all malaria interventions 
in Ethiopia
Q1; poorest quintile, Q5; richest quintile
Interventions Income group
Q1 Q2 Q3 Q4 Q5
Artemisinin-based combination 966,209 847,472 891,970 789,078 782,701
Long-lasting insecticide-treated bed nets 48,310 42,374 44,598 39,454 39,135
Indoor residual spray 27,537 24,153 25,421 22,489 22,307

























Artemisinin-based combination treatment (ACT) Long-lasting Insecticidal bed nets
Indoor residual spray Malaria Vaccine
Catastrophic health expenditure (CHE) averted
Fig. 2 Distribution of financial risk protection benefits (cases of CHE averted at 10% threshold) for each intervention per income quintile in Ethiopia
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probability of seeking inpatient care, intervention efficacy 
and OOP expenditures.
Discussion
In this paper, the health and financial benefits of UPF for 
malaria interventions were estimated across Ethiopian 
households at all income levels. Overall, all four interven-
tions showed substantial benefits, with ACT and LLIN 
accounting for the larger shares of malaria-related deaths 
and CHE cases averted.
All the interventions showed a greater number of 
deaths averted among the poorest 40% of the popula-
tion, averted similar OOP expenditures across all income 
groups, and relatively higher FRP benefits for the poor-
est 40%. Even if the poor had lower access for care and 
higher baseline malaria risk, for each of the intervention 
greater benefits would go toward the poor. This suggests 
that the malaria interventions analysed in this paper ben-
efit the worse-off and poor populations in remote areas 
of Ethiopia, who suffer the disease risk at most. Given the 
relatively lower malaria burden, the four malaria inter-
ventions would avert fewer deaths annually, as compared 
to, other interventions addressing childhood diarrhoea 
and pneumonia for example [51, 52]. Rapid decline of 
malaria deaths in Ethiopia over the last two decades and 
a relatively lower prevalence were the main reasons [6]. 
Among the four interventions, LLIN and ACT were the 
two strategies with the highest impact on malaria mor-
tality. In contrast, the malaria vaccine would prevent 
the smallest number of deaths averted (i.e. 38 per year) 
as compared to the other interventions. This is largely 
because the vaccine would be relatively less efficacious 
[14, 41]: only 2% of malaria-related child deaths would be 
prevented from the vaccine in this study.
Even though the rich had more access to health ser-
vices and less malaria burden, the private OOP sav-
ings would be similar across all income quintiles. This 
might be due to the fact that the poor and rich are 
Table 4 Sensitivity analyses on  the  impact on  deaths and  catastrophic health expenditure (CHE) cases averted 
when  long-lasting insecticide-treated bed nets (LLIN) input parameters vary across  income quintiles (Q1 = poorest; 
Q5 = richest), (low to high shows when input parameters are decreased or increased by 20%, respectively)
Sensitivity analysis LLIN Q1 Q2 Q3 Q4 Q5
Low High Low High Low High Low High Low High
Prevalence of malaria
 Deaths averted 45 68 30 45 35 53 21 32 20 30
 Private expenditures averted 38,710 58,070 33,900 58,070 36,090 50,850 31,830 54,130 31,810 47,720
 Cases of CHE averted 73 109 42 64 61 92 0 0 0 0
Malaria case fatality ratio
 Deaths averted 46 67 30 45 35 52 21 31 20 30
 Private expenditures averted 48,310 48,310 42,370 42,370 44,600 44,600 39,450 39,450 39,135 39,135
 Cases of CHE averted 91 91 53 53 76 76 0 0 0 0
Health services utilization
 Deaths averted 56 56 38 38 43 43 26 26 25 25
 Private expenditures averted 38,970 58,460 33,450 50,180 35,680 53,520 31,340 47,010 31,620 47,430
 Cases of CHE averted 73 110 42 63 61 91 0 0 0 0
Probability of inpatient visit
 Deaths averted 56 57 37 38 43 44 26 26 25 25
 Private expenditures averted 47,230 49,390 41,750 43,000 43,680 45,500 39,020 39,890 38,660 39,610
 Cases of CHE averted 73 109 42 64 61 91 0 0 0 0
Efficacy
 Deaths averted 45 68 30 45 35 52 21 32 20 30
 Private expenditures averted 38,650 57,970 33,900 50,850 35,680 53,520 31,560 47,350 31,310 46,960
 Cases of CHE averted 73 109 42 64 61 91 0 0 0 0
Cost inputs
 Government costs 2,625,170 3,963,500 2,632,890 3,971,210 2,621,860 3,960,190 2,634,170 3,972,500 2,628,660 3,966,990
OOP outpatient costs
 Deaths averted 56 56 38 38 43 43 26 26 25 25
 Private expenditures averted 39,850 56,770 34,600 50,150 36,680 52,520 32,040 46,860 31,820 46,450
 Cases of CHE averted 91 91 53 53 76 76 0 0 0 0
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spending similar OOP expenditures for malaria care. 
In absolute terms, the gains in private OOP expen-
ditures could be lower as compared to findings from 
other Ethiopian ECEAs [51–53]. This might be due to 
less OOP payments for malaria care as compared to 
the other diseases. As for the FRP benefits, LLIN and 
ACT prevented a higher number of CHE cases, and for 
all interventions, the greatest number of CHE cases 
averted would occur in the poorest income quintile. In 
addition, the annual cost of implementing IRS at a 10% 
incremental coverage for the at-risk population was 
about $33 million, 2 times higher than that of the LLIN 
intervention. This corresponds to more than 16% of 
malaria-related health care spending in Ethiopia [20]. 
Lastly, though ACT, LLIN, IRS, and malaria vaccine are 
critical for malaria control and elimination, these inter-
ventions would need to be combined with other inter-
ventions, such as behavioural change, correct use and 
implementation, to yield full impact.
Nevertheless, the analysis presented here has several 
limitations. First, the disease model was static and did 
not address the dynamics of malaria transmission. Sec-
ond, because of the unavailability of key input param-
eters by socioeconomic group, proxy input parameters 
were used. For example, the percentage who sought 
treatment for fever in the past 2  weeks was used as a 
proxy indicator for seeking malaria care. This might 
have overestimated malaria cases as there are other 
causes of fever among individuals (besides malaria). 
The Ethiopian 2016 DHS, the Malaria indicator survey 
and the ACT malaria consortium guidance on health 
equity analysis use health care utilisation due to fever in 
the past 2 weeks as a proxy for seeking care for malaria 
[9, 34, 35]. Third, due to the lack of disaggregated data, 
constant rates for case fatality ratio, intervention effec-
tiveness, and inpatient cost inputs were assumed across 
quintiles. Fourth, unit costs for the vaccine were not 
specific to Ethiopia. However, despite the limitations, 
the analysis is crucial as the findings could assist poli-
cymakers decide on which health interventions to roll-
out to reduce malaria disease burden affecting 60% of 
the Ethiopian population [9].
The ECEA can also answer some of the equity con-
cerns by providing valuable information on how malaria 
prevention or treatment strategies would decrease both 
malaria burden and financial risk incurred by households 
across various socioeconomic groups in Ethiopia. This 
study shows that malaria interventions could improve 
FRP across all income groups, especially among the bot-
tom income groups in Ethiopia. Furthermore, this analy-
sis can help reorienting malaria interventions to target 
elimination across selected segments of the population, 
especially among the poor.
Conclusions
All four malaria interventions would save more lives 
among the poor than among the rich. Preventing and 
treating malaria provides substantial health benefits and 
FRP, especially among poor Ethiopians. ACT and LLINs 
would generate the largest impact on malaria-related 
deaths averted and FRP benefits. Improving health equity 
and reducing poverty are major objectives of the Sustain-
able Development Goals, and the findings of the study 
presented here would provide insight for policymakers 
on how to prioritize malaria interventions for targeted 
population groups including the poorest.
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